[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598663":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":36,"locations":42,"responsibleParty":59,"collaborators":61,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":45,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":89,"whyStopped":45,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Nice","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1","ACTIVE_COMPARATOR","empaglifozine 10mg \u002F wash-out \u002F matching placebo",[13],"Drug: Empagliflozin 10 MG then Placebo",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2","matching placebo \u002F wash-out \u002F empaglifozine 10mg",[18],"Drug: Placebo then Empagliflozin 10 MG",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Empagliflozin 10 MG then Placebo","Taking Empagliflozin first",[9],[26],"EMPAGLIFLOZIN or iSGLT2",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Placebo then Empagliflozin 10 MG","Taking the Empagliflozin in second",[15],[26],[33],{"name":34,"affiliation":5,"role":35},"Vincent ESNAULT, MD-PHD","PRINCIPAL_INVESTIGATOR",[37],{"name":34,"role":38,"phone":39,"phoneExt":40,"email":41},"CONTACT","492038800","+33","esnault.v@chu-nice.fr",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"CHU Nice - Hôpital Pasteur 2",null,"Nice","Alpes-Maritimes","06000","France","FR",{"type":52,"coordinates":53},"Point",[54,55],7.26608,43.70313,{"lat":55,"lon":54},[58],{"name":34,"role":38,"phone":39,"phoneExt":40,"email":41},{"type":60,"investigatorFullName":45,"investigatorTitle":45,"investigatorAffiliation":45,"oldNameTitle":45,"oldOrganization":45},"SPONSOR",[62],{"name":63,"class":64},"Boehringer Ingelheim","INDUSTRY","100598663","phase-4-effect-of-empagliflozin-in-patients-with-egfr-between-10-and-20-mlmin173m2-100598663",false,"NCT07074418","Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml\u002FMin\u002F1.73m2","Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml\u002FMin\u002F1.73m2 - EMPA [10-20]","EMPA[10-20]","Inclusion Criteria:\n\n* type 2 diabetics,\n* age between 18 and 80 years,\n* RAS blockade at maximal tolerated dosage for 1 month,\n* eGFR (CKD-EPI) between 10 and 20 ml\u002Fmin\u002F1.73m2,\n* UACR \\> 300mg\u002Fg creatinine and UPCR \\> 500mg\u002Fg creatinine,\n* office systolic blood pressure \\> 110 mmHg,\n* stable dosage of antihypertensive drugs and diuretics for 1 month.\n\nExclusion Criteria:\n\n* any medical condition that, in the opinion of the investigator makes the participant not suitable for inclusion,\n* history of ketoacidosis in the past while on empagliflozin or any other SGLT2i class drugs,\n* participation in another clinical study with an investigational medicinal product (IMP) administered during the month before screening,\n* known hypersensitivity or intolerance to empagliflozin or any of the excipients of the product,\n* judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements,\n* no social insurance,\n* unwilling to give informed consent, vulnerable persons (minors, adults under guardianship or trusteeship, pregnant women, persons deprived of their liberty, persons unable to speak French).","ALL","18 Years","80 Years",{"count":77,"type":78},34,"ESTIMATED","INTERVENTIONAL",[81],"PHASE4","The proximal tubule remains the main site for sodium reabsorption in patients with advanced renal failure. The investigators therefore hypothesize that SGLT2i should still exert a significant natriuretic effect in patients with eGFR below 20 ml\u002Fmin\u002F1.73m2, and therefore should still decrease proteinuria with a potential renal protective effect.",[84],"Chronic Kidney Diseases",[86,87,88],"Chronic Kidney Disease","Nephrology","eGFR","NOT_YET_RECRUITING","2026-07-24",{"date":92,"type":93},"2026-07-27","ACTUAL",{"date":95,"type":78},"2026-09",{"date":97,"type":78},"2028-05",{"name":5,"class":6},1]